{
    "nct_id": "NCT04445701",
    "official_title": "A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "1. Confirmed diagnosis of symptomatic MM per IMWG criteria\n2. Measurable disease\n3. Relapsed or refractory to at least 3 prior systemic lines of therapy for MM\n4. Eastern Cooperative Oncology Group (ECOG) status 0-2\n5. Resolution of prior therapy-related adverse events\n6. Minimum of 2 weeks since last dose of cancer therapy or radiotherapy\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Previous Grade 3-4 infusion or hypersensitivity reaction\n2. Severe asthma or chronic obstructive pulmonary disease exacerbations requiring hospital admission or steroids\n3. Prior treatment with a checkpoint inhibitor (anti-PD-1, PD-L1 or CTLA-4) within 4 weeks.\n4. Prior treatment with a therapeutic agent that targets the CD47 axis.",
    "miscellaneous_criteria": "Key"
}